Published by
Reuters
Reuters
(Reuters) -The U.S. Food and Drug Administration on Friday approved Pfizer Inc’s nasal spray for migraine, giving patients access to a potentially fast-acting option to treat their headaches. The drug Zavzpret, also known as zavegepant, was approved for the treatment of acute migraine with or without aura in adults, the company said. Pfizer added Zavzpret and other migraine treatments, including Nurtec ODT, to it drugs portfolio through its $11.6 billion buyout of Biohaven Pharmaceutical last year. Zavzpret belongs to a class of drugs called calcitonin gene-related peptide inhibitors and will …